| 8.68 0 (0%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 10.62 | 1-year : | 10.93 |
| Resists | First : | 9.1 | Second : | 9.35 |
| Pivot price | 8.92  |
|||
| Supports | First : | 8.68 | Second : | 7.22 |
| MAs | MA(5) : | 8.72 |
MA(20) : | 8.98 |
| MA(100) : | 7.82  |
MA(250) : | 7.27 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 0 |
D(3) : | 3.9 |
| RSI | RSI(14): 46.6 | |||
| 52-week | High : | 10.73 | Low : | 4.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SAGE ] has closed above bottom band by 20.5%. Bollinger Bands are 47.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.68 - 8.74 | 8.74 - 8.79 |
| Low: | 8.55 - 8.62 | 8.62 - 8.68 |
| Close: | 8.58 - 8.68 | 8.68 - 8.76 |
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Tue, 02 Sep 2025
Sage Therapeutics, Inc. (SAGE) Bought by Supernus to Boost Neuropsychiatric Portfolio - Yahoo Finance
Thu, 31 Jul 2025
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - GlobeNewswire
Thu, 31 Jul 2025
Supernus completes acquisition of Sage Therapeutics for $8.50 per share - Investing.com
Wed, 30 Jul 2025
Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Wed, 30 Jul 2025
Sage Therapeutics Announces Second Quarter 2025 Financial Results - Business Wire
Mon, 30 Jun 2025
Sage to lay off most staff amid Supernus buyout - BioPharma Dive
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 10.3 (%) |
| Held by Institutions | 83.5 (%) |
| Shares Short | 2,220 (K) |
| Shares Short P.Month | 5,250 (K) |
| EPS | -4.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.88 |
| Profit Margin | 0 % |
| Operating Margin | -171.2 % |
| Return on Assets (ttm) | -33.8 % |
| Return on Equity (ttm) | -60.5 % |
| Qtrly Rev. Growth | 265.7 % |
| Gross Profit (p.s.) | -1.2 |
| Sales Per Share | 1.12 |
| EBITDA (p.s.) | -4.82 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -289 (M) |
| Levered Free Cash Flow | -178 (M) |
| PE Ratio | -1.78 |
| PEG Ratio | 0 |
| Price to Book value | 1.47 |
| Price to Sales | 7.73 |
| Price to Cash Flow | -1.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|